Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients statewide.

Today's health news includes NIH grants reinstated, RFK Jr.'s new vaccine recommendations, and esketamine therapy results.

While its effectiveness is still being researched, clinical therapists across the country and here at Bryan Medical say it’s mostly beneficial for treatment-resistant depression patients.

Reports of Elon Musk’s drug use have renewed attention to ketamine, a powerful anesthetic.

A ketamine derivative, esketamine under the brand name Spravato, is FDA-approved as a nasal spray to treat depression in adults, according to the National Institute on Drug Abuse.

There’s also a nasal spray called esketamine. While the drug isn’t pure ketamine, but rather a component of it, it’s similar enough that it often gets lumped under the ketamine therapy umbrella.

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one roof would be ideal.

Medicare covers some forms of ketamine, but it doesn’t cover ketamine therapy for mental health conditions. Read more.

This is the fifth and final article in a series on value-based care and the 4 challenges health care organizations must overcome.